An Italian Real-World Study Highlights the Importance of Some Clinicopathological Characteristics Useful in Identifying Metastatic Breast Cancer Patients Resistant to CDK4/6 Inhibitors and Hormone Therapy

Roberta Maltoni,Andrea Roncadori,William Balzi,Massimiliano Mazza,Fabio Nicolini,Michela Palleschi,Paola Ulivi,Sara Bravaccini
DOI: https://doi.org/10.3390/biomedicines12030498
IF: 4.757
2024-02-23
Biomedicines
Abstract:Background: Cyclin-dependent kinase 4 and 6 (CDK4 and CDK6) inhibitors have changed the therapeutic management of hormone receptor-positive (HR+) metastatic breast cancer (mBC) by targeting the cell cycle machinery and overcoming endocrine resistance. However, a large number of patients present disease progression due to cancer cells resisting CDK4/6 inhibitors. Our research considers which clinicopathological characteristics could be useful in identifying patients who might respond to CDK4/6 inhibitors by analyzing a retrospective case series of patients with HR+ mBC who were treated with hormone therapy plus CDK4/6 inhibitors. Methods: Approximately 177 mBC patients were enrolled, of whom 66 were treated with CD4/6 inhibitors plus letrozole and 111 were treated with CDK4/6 inhibitors and fulvestrant. A multistate model was used. Results: A low body surface area and older age were associated with an increased risk of developing neutropenia. A high Ki67 index, the presence of visceral metastases, and not having previously undergone adjuvant chemotherapy were prognostic factors of disease progression/death. As expected, some of the neutropenic patients who had previously undergone multiple lines of treatment were at a higher risk of disease progression/death. Furthermore, neutropenia status was associated with a more than doubled risk of progression/death compared to patients without neutropenia (HR = 2.311; p = 0.025). Conclusions: Having identified certain factors that could be associated with the development of neutropenia and considering that neutropenia itself is associated with an increased risk of progression, we believe that the baseline characteristics should be taken into account to reduce cases of neutropenia and disease progression.
biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy
What problem does this paper attempt to address?
### Problems the paper attempts to solve This paper aims to explore whether certain clinicopathological features can be used to identify metastatic breast cancer (mBC) patients who are resistant to CDK4/6 inhibitors and hormone therapy. Specifically, the researchers hope to find out which clinicopathological features can help identify patients who are likely to respond to CDK4/6 inhibitors and hormone therapy by analyzing a case series in the real - world in Italy. ### Background 1. **The role of CDK4/6 inhibitors**: - CDK4/6 inhibitors target the cell - cycle mechanism, overcome endocrine resistance, and have changed the treatment management of hormone receptor - positive (HR+) metastatic breast cancer (mBC). - However, many patients experience disease progression due to the resistance of cancer cells to CDK4/6 inhibitors. 2. **Research objectives**: - Identify clinicopathological features associated with CDK4/6 inhibitor resistance. - Analyze how these features affect patients' treatment response and prognosis. ### Methods 1. **Research design**: - Retrospective analysis of a case series of HR+ mBC patients treated at IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”. 2. **Data sources and patient selection**: - Data were obtained through the electronic medical record system. - Female patients who received first - line or second - line treatment between July 5, 2017 and April 13, 2021 and subsequently received hormone therapy plus CDK4/6 inhibitors were included. 3. **Statistical methods**: - A multi - state model was used to analyze the transition from the treatment state to the neutropenia state and then to the disease progression/death state. - The Cox proportional - hazards model was used to evaluate the impact of various factors on the risk of disease progression and death. ### Results 1. **Baseline characteristics**: - A total of 177 metastatic breast cancer patients were included, of which 66 (37.3%) received CDK4/6 inhibitors plus letrozole, and 111 (62.7%) received CDK4/6 inhibitors plus fulvestrant. - The median age of the patients was 63 years, 85.9% of the patients were post - menopausal, and 49.2% of the patients had a BMI higher than 25 kg/m². 2. **Relationship between clinicopathological features and disease progression**: - A high Ki67 index, the presence of visceral metastases, and no prior adjuvant chemotherapy were prognostic factors for disease progression/death. - Patients with a low body surface area and those over 65 years old were more likely to develop neutropenia. - The neutropenia state was associated with an increased risk of disease progression/death (HR = 2.311; p = 0.025). ### Discussion 1. **Comparison with existing studies**: - Multiple studies have shown that CDK4/6 inhibitors combined with hormone therapy significantly improve the progression - free survival (PFS) of endocrine - sensitive or - resistant breast cancer patients. - However, many patients still do not respond or are resistant to these treatments, and there is currently a lack of reliable biomarkers to pre - screen responders or resistant patients. 2. **Significance of the study**: - Identifying some clinicopathological features associated with CDK4/6 inhibitor resistance helps to consider these baseline variables when choosing a treatment plan, thereby reducing the risk of neutropenia and disease progression. - For high - risk patients (such as those with a high Ki67 index and visceral crisis), clinicians should consider using chemotherapy. ### Conclusion This study identified some clinicopathological features associated with CDK4/6 inhibitor resistance by analyzing a case series in the real - world in Italy. These findings help to optimize treatment strategies and reduce the risk of neutropenia and disease progression. In the future, it is necessary to further expand the sample size to verify and improve these results.